TSE:MDP Q2 EPS Forecast Boosted by Raymond James Financial

Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Investment analysts at Raymond James Financial raised their Q2 2026 earnings per share estimates for shares of Medexus Pharmaceuticals in a research note issued to investors on Wednesday, August 13th. Raymond James Financial analyst M. Freeman now forecasts that the company will post earnings of $0.00 per share for the quarter, up from their previous forecast of ($0.07). The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Raymond James Financial also issued estimates for Medexus Pharmaceuticals' Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.10 EPS, Q2 2027 earnings at $0.21 EPS, Q3 2027 earnings at $0.29 EPS, Q4 2027 earnings at $0.29 EPS, FY2028 earnings at $1.08 EPS, FY2029 earnings at $1.79 EPS and FY2030 earnings at $2.13 EPS.

Separately, Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a research note on Monday, August 11th. Four analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of C$5.49.

Medexus Pharmaceuticals Trading Up 0.7%

Shares of TSE:MDP traded up C$0.02 during midday trading on Monday, hitting C$2.87. 2,800 shares of the stock were exchanged, compared to its average volume of 72,214. The stock has a market cap of C$64.25 million, a P/E ratio of 13.72 and a beta of 1.96. Medexus Pharmaceuticals has a twelve month low of C$1.71 and a twelve month high of C$5.56. The company has a 50 day moving average price of C$2.92 and a 200-day moving average price of C$2.78.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.